Subject(s)
Humans , /administration & dosage , /immunology , /prevention & control , Immunity, HumoralABSTRACT
Objectives. Vaccination against SARS-CoV-2 is essential to mitigate the personal, social and global impact of the coro navirus disease (COVID-19) as we move from a pandemic to an endemic phase. Vaccines are now required that offer broad, long-lasting immunological protection from infection in addi tion to protection from severe illness and hospitalisation. Here we present a review of the evidence base for a new COVID-19 vaccine, PHH-1V (Bimervax®; HIPRA HUMAN HEALTH S.L.U), and the results of an expert consensus. Materials and methods. The expert committee consisted of Spanish experts in medicine, family medicine, paediatrics, immunology, microbiology, nursing, and veterinary medicine. Consensus was achieved using a 4-phase process consisting of a face-to-face meeting during which the scientific evidence base was reviewed, an online questionnaire to elicit opinions on the value of PHH-1V, a second face-to-face update meet ing to discuss the evolution of the epidemiological situation, vaccine programmes and the scientific evidence for PHH-1V and a final face-to-face meeting at which consensus was achieved. Results. The experts agreed that PHH-1V constitutes a valuable novel vaccine for the development of vaccination programmes aimed towards protecting the population from SARS-CoV-2 infection and disease. Consensus was based on evidence of broad-spectrum efficacy against established and emerging SARS-CoV-2 variants, a potent immunological re sponse, and a good safety profile. The physicochemical proper ties of the PHH-1V formulation facilitate handling and storage appropriate for global uptake. Conclusions- The physicochemical properties, formula tion, immunogenicity and low reactogenic profile of PHH-1V confirm the appropriateness of this new COVID-19 vaccine (AU)
Objetivos. La vacunación frente al SARS-CoV-2 es funda mental para mitigar el impacto personal, social y global de la enfermedad por coronavirus (COVID-19) a medida que pasa mos de una fase pandémica a una endémica. Actualmente se requieren vacunas que ofrezcan una protección inmunológi ca amplia y duradera contra la infección, además de proteger de la enfermedad grave y la hospitalización. En este artículo se presenta una revisión de la evidencia científica para una nueva vacuna COVID-19, PHH-1V (Bimervax®; HIPRA HUMAN HEALTH S.L.U) y los resultados de un consenso de expertos. Material y métodos. El comité de expertos incluyó ex pertos españoles en medicina, medicina de familia, pediatría, inmunología, microbiología, enfermería y veterinaria. El con senso se logró mediante un proceso de 4 fases que constó de una reunión presencial durante la cual se revisó la evidencia científica, un cuestionario en remoto para obtener opinions sobre el valor de PHH-1V, una segunda reunión presencial de actualización y discusión sobre la evolución de la situación epidemiológica, los programas de vacunas y la evidencia cien tífica para PHH-1V y una última reunión presencial en la que se obtuvo el consenso. Resultados. Los expertos coincidieron en que PHH-1V constituye una vacuna novedosa y valiosa para el desarrollo de programas de vacunación destinados a proteger a la población de la infección y enfermedad por SARS-CoV-2. El consenso se basó en la evidencia del amplio espectro de eficacia contra las variantes establecidas y emergentes del SARS-CoV-2, una res puesta inmunológica potente y un buen perfil de seguridad. Las propiedades fisicoquímicas de la formulación de PHH-1V facilitan la manipulación y el almacenamiento apropiados para la absorción global. Conclusiones. Las propiedades fisicoquímicas, formula ción, inmunogenicidad y bajo perfil reactogénico de PHH-1V confirman la idoneidad de esta nueva vacuna COVID-19 (AU)
Subject(s)
Humans , Coronavirus Infections/prevention & control , Viral Vaccines/administration & dosage , Vaccines, DNA/administration & dosage , Drugs, InvestigationalABSTRACT
Background and objectives: Influenza vaccination rates among medical students (MSs) are below the standards recommended in hospitals where influenza vaccination is not mandatory. We carried out a comparative study in two Spanish university hospitals to reassert this fact and evaluated the impact on vaccination rates of a specific program aimed at promoting influenza vaccination among MSs.Methods: A descriptive cross-sectional study was performed describing influenza vaccination rates and motivations for vaccination during the 2017/18 campaign among MSs in two hospitals affiliated to the same university. We subsequently performed a community-based intervention study during the 2018/19 campaign evaluating the impact of a strategy for promoting influenza vaccination, comparing the hospital where the intervention took place (hospital A) with the one where it did not take place (hospital B).Results: During de 2017/18 campaign the overall influenza vaccination rate was 44.8%, with no differences between hospitals A and B (difference: 3.9%; 95% CI: -4.36-12.16; p-value = .4). During the 2018/19 campaign, vaccination rate increased to 76.4% in hospital A, with significant differences compared with the previous campaign in the same hospital (29.8%; OR 5.00; 95% CI: 3.14-8.3; p-value = .0001) and with that observed in hospital B in the same campaign (21.1%; 95% CI: 13.38-28.82; p-value <.001).Conclusions: Influenza vaccination rates among MSs in two Spanish university affiliated hospitals were below the recommended standards. A new reproducible strategy for promoting influenza vaccination with a specific approach toward MSs achieved a significant improvement in vaccination rate.
Subject(s)
Influenza Vaccines , Influenza, Human , Students, Medical , Attitude of Health Personnel , Cross-Sectional Studies , Health Personnel , Hospitals, University , Humans , Influenza, Human/prevention & control , VaccinationABSTRACT
No disponible
Subject(s)
Humans , Male , Female , Middle Aged , Research Report/standards , Pneumonia, Pneumococcal/epidemiology , Pneumonia, Pneumococcal/immunology , Pneumonia, Pneumococcal/prevention & control , Heptavalent Pneumococcal Conjugate Vaccine/immunology , Vaccination/methods , Health Services Coverage/trends , Cohort Studies , Treatment Outcome , Evaluation of the Efficacy-Effectiveness of Interventions , Risk GroupsABSTRACT
A systematic screening for measles, mumps, rubella (MMR) and varicella zoster virus (VZV) in HIV-positive adult immigrants in Spain was evaluated, and factors associated with MMR and VZV vaccines' indication were studied. Every HIV-positive immigrant was tested for VZV and MMR-IgG. MMR vaccine was indicated to patients with lymphocytes CD4+ >200 cells/mm³ and a negative measles-IgG, a negative mumps-IgG and/or a negative rubella-IgG. VZV vaccine was indicated to every VZV-IgG negative patient with CD4+ >400 cells/mm³. In total, 289 patients were screened; seroprevalence was 95.2%, 92.2%, 70.3% and 89.3% for VZV, measles, mumps and rubella IgG, respectively. Having a negative VZV-IgG was statistically associated with coming from sub-Saharan Africa (prevalence ratio [PR]: 6.52; 95% CI: 1.71-24.84; p=0.006), while having secondary education was a protective factor (PR: 0.25; 95% CI: 0.07-0.97; p=0.045). Fourteen patients (4.8%) had indication of VZV vaccine; vaccination was feasible in 21.4% of them at first visit. Eighty-one patients (29.7%) had indication of MMR vaccine, most of them due to mumps-IgG negative (53.1%) or rubella-IgG negative (24.7%). Age < 30 years at first visit was the only factor statistically associated with MMR vaccine indication (PR: 1.47; 95% CI: 1.02-2.11; p=0.04). According to CD4+ cell counts, vaccination was feasible in 71.6% of patients at first visit. In conclusion, more than a third of HIV-infected immigrant patients are susceptible to at least one easily preventable infectious disease. Especial attention should be given to immigrant women of childbearing age.
Subject(s)
Chickenpox Vaccine/immunology , Emigrants and Immigrants/statistics & numerical data , HIV Infections/immunology , Mass Screening/methods , Measles-Mumps-Rubella Vaccine/immunology , Adult , Africa South of the Sahara/ethnology , Chickenpox/epidemiology , Chickenpox/immunology , Chickenpox/prevention & control , Cross-Sectional Studies , Female , HIV Infections/epidemiology , Herpesvirus 3, Human/immunology , Humans , Male , Measles/epidemiology , Measles/immunology , Measles/prevention & control , Measles virus/immunology , Mumps/epidemiology , Mumps/immunology , Mumps/prevention & control , Mumps virus/immunology , Rubella/epidemiology , Rubella/immunology , Rubella/prevention & control , Rubella virus/immunology , Spain/epidemiologyABSTRACT
Objetivo. El objetivo de este estudio ha sido evaluar la frecuencia y las características de las hospitalizaciones por cáncer de cuello de útero en la Comunidad de Madrid, así como estimar el consumo de recursos y costes asociados al tratamiento hospitalario de la enfermedad. Métodos. Se ha realizado un estudio retrospectivo utilizando la información del sistema nacional de vigilancia de datos hospitalarios (Conjunto Mínimo Básico de Datos) sobre las hospitalizaciones por neoplasia maligna de cérvix en la Comunidad de Madrid. Adicionalmente, se ha recogido información de las historias clínicas de las pacientes hospitalizadas por cáncer de cuello de útero en el Hospital Universitario 12 de Octubre de Madrid para el análisis de consumo de recursos y costes. Resultados. Durante el periodo 1999-2002 se notificaron una media anual de 667 hospitalizaciones por cáncer de cuello de útero en los hospitales de la Comunidad de Madrid. La tasa de hospitalización fue de 30,7 por 100.000 mujeres ≥ 20 años y el número medio de hospitalizaciones anuales por paciente de 2,2. Se registraron 126 defunciones entre las mujeres hospitalizadas por cáncer de cuello de útero durante el período de estudio (media anual de 32 fallecimientos). El coste medio por paciente del tratamiento hospitalario del cáncer de cuello de útero se ha estimado en 5.247 . Conclusión. Cada año se notifican casi 700 hospitalizaciones por cáncer de cuello de útero en hospitales de la Comunidad de Madrid, con un coste anual para el sistema sanitario de unos 3,5 millones de (AU)
Objective. The aim of this study was to assess the frequency and characteristics of cervical cancer hospitalizations in the Autonomous Region of Madrid, and to estimate the resource consumption and costs related to hospital treatment of the disease. Methods. A retrospective study was conducted by using information of the cervical cancer patients hospitalized in the Autonomous Region of Madrid from the national surveillance system for hospital data, Conjunto Mínimo Básico de Datos. Data on resource consumption for costs analysis was collected from clinical records of women admitted to Hospital Universitario 12 de Octubre of Madrid with cervical cancer. Results. During the study period (1999-2002) an annual average of 667 hospitalizations with cervical cancer in the Autonomous Region of Madrid hospitals were reported. Hospitalization rate were 30.7 per 100,000 women ≥ 20 years of age and the average number of hospitalizations per patient was 2.2. A total of 126 deaths among hospitalized women were reported during the study period (average annual number of 32 deaths). The mean cost per patient of the hospital treatment was estimated in 5.247 . Conclusion. Each year more approximately 700 cervical cancer cases are notified in the Autonomous Region of Madrid hospitals. These represent an annual expenditure for the health care system of about 3,5 millions (AU)
Subject(s)
Humans , Female , Adult , Middle Aged , Hospitalization/statistics & numerical data , Hospitalization/trends , Uterine Neoplasms/epidemiology , Papilloma/epidemiology , /trends , Spain/epidemiology , Retrospective Studies , Epidemiological Monitoring , Costs and Cost Analysis/methods , /statistics & numerical data , /trendsABSTRACT
No disponible
